Saturday 17 October 2026 Export EVH’s income statement to Excel — free account

Evolent Health, Inc

EVH Healthcare Health Information Services

Evolent Health, Inc’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 26.6% from fiscal 2024. In the quarter to June 2026, revenue grew 46.9%, EPS grew 43.2%, free cash flow grew 58.7% and total debt rose 49.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.57 0.30 −6.16%

Follow EVH

Alert me

Market cap: $550.6M
P/E: 0.0×
Fwd P/E: −5.8×
Dividend yield: —
F-score: 5/9
Altman Z: −0.43
Beneish M: −4.60
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.04

Total sells 0.33

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	1	—	—

Insider Ownership 9.00%

Capital & Financial Ratios $m

Market Cap 550.60

Revenue 2,097.02

Net Income (504.99)

Free Cash Flow 24.34

Net Debt 827.77

Current Ratio 1.24

Debt/Equity 2.52

P/E ratio 0.00

Fwd P/E (5.82)

P/S ratio 0.25

P/B ratio 1.34

Past 5Y EPS Growth —

This Y EPS Growth 89.21%

Next Y EPS Growth 108.99%

Next Y revenue growth 40.44%

Next 5Y EPS Growth 74.81%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 6.49%

10-year low 10-year high

P/B against its own 10 years 47.95%

10-year low 10-year high

EV/Sales against its own 10 years 7.67%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	207	163	178	139
Receivables	447	415	310	449
Inventory	—	—	—	—
Other	—	—	—	—
	684	607	506	611

	2023	2024	2025	Q'26
Payables	48	96	60	39
ST’ Debt	—	—	—	—
Other	404	319	192	378
	674	716	385	493

Compound Annual Growth %

	10y	5y	3y
Sales	34.49%	15.20%	11.54%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(7.79%)	(7.69%)	(21.53%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	496	653	—	—	—
’25	484	444	480	469	1,876
’24	640	647	621	647	2,555
’23	428	469	511	556	1,964
’22	297	320	353	382	1,352
’21	215	222	222	248	908
’20	221	217	240	247	925

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(9)	—	—	—
’25	5	(30)	16	49	39
’24	5	21	19	(26)	19
’23	(8)	1	61	89	143
’22	(57)	14	(3)	36	(12)
’21	(48)	(24)	45	67	39
’20	(21)	38	(20)	(13)	(16)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(7)	(16)	—	—	—
’25	(4)	(39)	7	41	5
’24	0	14	12	(32)	(6)
’23	(17)	(6)	54	83	114
’22	(66)	4	(13)	25	(50)
’21	(54)	(30)	38	59	14
’20	(28)	28	(27)	(19)	(46)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.24)	(0.25)	—	—	—
’25	(0.63)	(0.44)	(0.24)	(3.84)	(5.07)
’24	(0.22)	(0.06)	(0.27)	(0.27)	(0.81)
’23	(0.24)	(0.37)	(0.30)	(0.36)	(1.28)
’22	(0.06)	(0.05)	0.02	(0.11)	(0.20)
’21	(0.12)	(0.11)	(0.15)	(0.06)	(0.44)
’20	(0.92)	(2.38)	(0.44)	(0.17)	(3.94)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	8.14	10.30	12.33	5.50	3.50	15.80	21.36	23.33	10.53	3.50	Analyst estimates 2026–2028 Powerpack
	High	26.84	27.50	29.05	21.73	16.78	34.60	39.78	36.70	35.00	12.98
People
People	Employees	2,400	2,600	3,800	3,400	2,900	3,500	5,100	4,700	4,500	4,200
	Revenue/emp, $m	0.11	0.17	0.17	0.20	0.32	0.26	0.27	0.42	0.57	0.45
Income, $m
Income, $m	Revenue	254	435	627	687	925	908	1,352	1,964	2,555	1,876
	Gross margin, %	38.95	38.07	47.72	25.34	24.66	27.58	23.42	23.45	14.38	21.31
	EBT	(238)	(76)	(54)	(330)	(331)	(30)	(62)	(202)	(63)	(535)
	EBT margin, %	(93.45)	(17.57)	(8.64)	(48.02)	(35.75)	(3.28)	(4.59)	(10.31)	(2.47)	(28.50)
	Net income	(227)	(70)	(54)	(306)	(334)	(38)	(19)	(113)	(62)	(535)
	Depreciation	178	33	50	276	313	91	93	138	127	528
Per share, $
Per share, $	Revenue	5.64	6.76	8.11	8.34	10.89	10.55	14.43	17.65	22.28	16.43
	Earnings	(3.55)	(0.94)	(0.68)	(3.67)	(3.94)	(0.44)	(0.20)	(1.28)	(0.81)	(5.07)
	Cash flow	(0.79)	(0.43)	(0.27)	(0.52)	(0.19)	0.45	(0.12)	1.28	0.16	0.34
	Capex	(0.34)	(0.43)	(0.51)	(0.43)	(0.35)	(0.29)	(0.41)	(0.26)	(0.22)	(0.30)
	Free cash flow	(1.13)	(0.87)	(0.78)	(0.95)	(0.54)	0.16	(0.53)	1.02	(0.05)	0.04
	Book value	20.26	16.26	15.38	11.28	7.30	8.06	9.17	11.20	10.39	3.64
	Shares, m	45	64	77	82	85	86	94	111	115	114
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	2.64	1.89	2.46	1.08	1.47	2.62	1.87	1.89	0.51	0.24
	P/B	0.74	0.79	1.30	0.80	2.20	3.43	2.94	3.47	1.29	1.10
	EV/Sales	2.27	1.48	2.20	1.33	1.40	2.48	2.03	2.08	0.63	0.67
	EV/FCF	(11.32)	(11.54)	(22.94)	(11.72)	(28.26)	163.85	(54.86)	35.95	(263.90)	262.75
Cash, $m
Cash, $m	Operating cash flow	(36)	(28)	(21)	(43)	(16)	39	(12)	143	19	39
	Capex	(16)	(28)	(40)	(36)	(29)	(25)	(38)	(29)	(25)	(34)
	Free cash flow	(51)	(56)	(60)	(78)	(46)	14	(50)	114	(6)	5
Balance, $m
Balance, $m	Working capital	133	245	219	36	144	78	45	9	(108)	121
	Total debt	120	121	221	294	263	216	413	597	491	971
	Net debt	(93)	(179)	(162)	171	(70)	(126)	210	390	327	793
	Shareholders’ equity	912	1,046	1,189	929	620	694	859	1,246	1,191	415
Returns, %
Returns, %	ROA	(14.42)	(4.83)	(3.47)	(18.75)	(23.29)	(2.69)	(1.18)	(6.33)	(3.58)	(26.08)
	ROIC	(18.12)	(5.25)	(2.89)	(17.55)	(29.89)	(4.67)	0.21	(2.72)	(1.67)	(21.22)
	ROE	(17.30)	(6.20)	(4.71)	(28.51)	(43.17)	(5.73)	(2.47)	(14.76)	(9.03)	(81.81)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PHR Phreesia, Inc.	$685.3M	64.4×	23.5×	+10.41% (above 0%: growing)	+200.00% (above 0%: growing)	+43.51% (above 0%: growing)	66.64%	5.88%	Compare
MDRX Veradigm Inc.	$654.5M	— (loss-making)	— (loss-making)	−9.74% (below 0%: shrinking)	n/m	−66.33% (below 0%: shrinking)	50.53%	(37.41%)	Compare
SOPH SOPHiA GENETICS SA	$620.6M	— (loss-making)	— (loss-making)	+27.22% (above 0%: growing)	n/m	+6.50% (above 0%: growing)	64.61%	(86.03%)	Compare
WEAV Weave Communications, Inc.	$594.5M	— (loss-making)	— (loss-making)	+15.52% (above 0%: growing)	n/m	+94.33% (above 0%: growing)	72.03%	(6.49%)	Compare
EVH Evolent Health, Inc	$550.6M	— (loss-making)	— (loss-making)	+46.86% (above 0%: growing)	n/m	+58.67% (above 0%: growing)	12.39%	(1.47%)
NRC National Research Corporation	$466.9M	80.6×	4.9×	+3.98% (above 0%: growing)	n/m	+101.49% (above 0%: growing)	61.67%	(9.15%)	Compare
CTEV Claritev Corporation	$404.4M	— (loss-making)	— (loss-making)	+6.59% (above 0%: growing)	n/m	+49.10% (above 0%: growing)	73.72%	9.09%	Compare
CARL Carlsmed, Inc.	$380.9M	— (loss-making)	— (loss-making)	+56.75% (above 0%: growing)	n/m	−6.84% (below 0%: shrinking)	76.78%	(58.27%)	Compare
CSLT Castlight Health, inc.	$332.4M	— (loss-making)	— (loss-making)	−0.86% (below 0%: shrinking)	n/m	+106.49% (above 0%: growing)	66.20%	(5.42%)	Compare
Median of peers	$530.7M	—	—	+8.50%	—	+46.30%	66.42%	(7.82%)

All 51 Health Information Services stocks →

Evolent Health, Inc (EVH) key facts

Concern: Evolent Health, Inc’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 26.6% from fiscal 2024.
Evolent Health, Inc (EVH) is a Health Information Services company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, EVH traded at $4.57, a market capitalization of $550.6 million.
Return on equity was −81.8% and debt-to-equity 2.52.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −0.43 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.